On the Record · Opko Health
Opko Health acquisitions, on the record
The businesses Opko Health bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
ModeX Therapeutics, Inc.Word for word“On May 9, 2022, the Company entered into the ModeX Merger Agreement (as defined in Note 1 to the audited consolidated financial statements contained in this Annual Report on Form 10-K), pursuant to which we acquired ModeX.” 10-K for 2023 | agreed acquisition | May 9, 2022 | — |
GeneDx LLC (f/k/a GeneDx, Inc.)Word for word“Pursuant to the GeneDx Merger Agreement, on April 29, 2022, GeneDx Holdings Corp. (formerly, Sema4), acquired GeneDx from us for an upfront payment of $150 million in cash, together with 80.0 million shares of GeneDx Holdings Common Stock, subject to a customary purchase price adjustment mechanism.” 10-K for 2023 | agreed divestiture | On April 29, 2022 | an upfront payment of $150 million in cash, together with 80.0 million shares of GeneDx Holdings Common Stock, subject to a customary purchase price adjustment mechanism |
Transition TherapeuticsWord for word“In 2016, we acquired Transition Therapeutics, which was developing multiple drug candidates that included OPK88003 (a long acting oxyntomodulin) and OPK88004 (SARM), each of which is licensed from Eli Lilly and has patents granted worldwide covering the compounds and their use in their respective indications.” 10-K for 2023 | acquisition | 2016 | — |
EirGenWord for word“During 2015, we acquired EirGen, a specialty pharmaceutical company based in Ireland.” 10-K for 2023 | acquisition | During 2015 | — |
select assets of BioReferenceWord for word“The BioReference Transaction closed on September 16, 2024, and upon closing, Labcorp paid to the Company aggregate consideration of $237.5 million in cash, subject to certain adjustments as set forth in the Labcorp Asset Purchase Agreement.” 10-K for 2024 | agreed divestiture | The BioReference Transaction closed on September 16, 2024 | $237.5 million in cash |
GeneDx LLCWord for word“We originally acquired shares of GeneDx Holdings in the 2022 disposition of our former subsidiary, GeneDx LLC (“GeneDx”) and subsequently acquired additional shares in an underwritten offering by GeneDx Holdings.” 10-K for 2024 | divestiture | 2022 | — |
BioReference's oncology diagnostics business and related clinical testing services assetsWord for word“On September 15, 2025, we consummated the sale of certain assets of BioReference to Labcorp (the “Oncology Transaction”), pursuant to an agreement entered into on March 10, 2025 (the “Labcorp Oncology Purchase Agreement”). ” 10-K for 2025 | divestiture | September 15, 2025 | — |
BioReference's laboratory testing businesses focused on clinical diagnostics, reproductive health, and women's health across the United States, excluding New York and New JerseyWord for word“• September 2024 BioReference Transaction: We completed the sale of laboratory testing businesses focused on clinical diagnostics, reproductive health, and women's health across the United States, excluding New York and New Jersey, for $237.5 million in cash.” 10-K for 2025 | divestiture | September 2024 | $237.5 million |
ModeXWord for word“In May 2022, we acquired ModeX, a biotech company developing multi-specific immune therapies focused on oncology, immunology and infectious diseases.” 10-K for 2025 | acquisition | May 2022 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses |
|---|---|---|
| 2016-12-31 | −$15.9 million | — |
| 2017-12-31 | $0 | — |
| 2018-12-31 | $0 | — |
| 2019-12-31 | $0 | — |
| 2020-12-31 | $0 | — |
| 2021-12-31 | $4 million | — |
| 2022-12-31 | $1.8 million | $0 |
| 2023-12-31 | $0 | $0 |
| 2024-12-31 | $0 | $210.4 million |
| 2025-12-31 | — | $197.8 million |
Deal filings since 2016
- 2026-10-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-08-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-04-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-03-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-03-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-09-16 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2024-07-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-03-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-01-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-06-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-03-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-02-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-07-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-05-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-05-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-01-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-09-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-07-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-06-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-06-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-05-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-03-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-05-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-10-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-02-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-11-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-03-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-12-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-10-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-08-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-03-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-06-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-05-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Opko Health’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.